Overview

A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2015-12-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy (superiority to placebo) of ipragliflozin based on the changes in HbA1C, as well as its safety, in patients with type 2 diabetes mellitus in combination with an insulin preparation once daily for 16 weeks. The long-term (52 weeks) safety and the persistence of the efficacy will also be evaluated.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Insulin
Insulin, Globin Zinc
Ipragliflozin